UNITAID can address HCV/HIV co-infection

摘要

In the first days of March, the governing body of UNITAID, the organisation financed mainly through a levy on air tickets, will decide on a new 4-year strategy. A 5-year evaluation1 praised UNITAID's successful "market impact" model for improving access to HIV, tuberculosis, and malaria products through lowering prices, improving supply, or introducing new products. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.